-
Most Recent
Search Results
240 results for frx
The Market Rally Resembles a Dog On a Bone
To this point in the year stocks, bonds, gold, oil and gas markets are working just fine, and my charts suggest more to come. Read…
41 S&P 500 Stocks Hit New Lows in Early Tuesday Trading
S&P 500 dips slightly Tuesday, with Urban Outfitters, Abercrombie & Fitch and Citigroup among losers by midday.
MRK: Merck Sells Consumer Business to Double Down on Blockbusters
Swinging for the fences, MRK sold one of the industry’s crown jewels in exchange for an opportunity to find new blockbuster drugs. It’s a risky…
Is Big Pharma Resistant to Antibiotics?
Less profitable drugs take a backseat despite health risks
Everyone’s Chasing SpaceX, but We’re Going After Something Better
In today’s Smart Money, let’s dig into why investing in the companies downstream of SpaceX is a better choice than buying a stake in the…
Actavis Prescribes Profits via M&A and Generic Drugs
This specialty pharmaceutical company is consolidating its way into becoming a post-Affordable Care Act powerhouse.
No Payday In Sight for Alzheimer’s Drug Stocks
At best, the drugs on the market are stopgap measures. They can’t cure the disease.
Is it Time to Follow Ichan Out of Amgen — and Other Biotechs?
Investor Carl Ichan recently dumped several biotechs. However, Amgen’s sales are strong, and with other positives, it’s possible he cut bait too soon.
Johnson & Johnson, Forest Labs Will Make You Sick
Johnson & Johnson beat expectations but its profits were down; Forest Labs missed and has a plunging profit forecast. Investors should be wary of both…
2 Biotech Stocks to Buy After Earnings
Actavis (ACT) and Jazz Pharmaceuticals (JAZZ) reported outstanding Q3 earnings and are strong biotech stocks to buy.
Wall Street’s 10 Biggest Deals of Q1 2014
The year is off to a hot start for M&A, as Facebook, Google, IBM and others got busy pulling off Q1’s biggest deals.
3 Mutual Funds Poised to Profit From Obamacare
By Bill Wysor — There are winners and losers in the changing healthcare industry, but let seasoned mutual fund managers do the legwork for you.
Buy Icahn Enterprises to Play Apple Stock with Less Risk
For a low-risk way to play a bounce back in Apple stock, let Carl Icahn and a bet on Icahn Enterprises stock lead the way.
4 Best Mutual Funds at Vanguard Now
Here are four of the top mutual fund investments from Vanguard now.
The Trade Everyone’s Missing in the Peace Rally
Iran peace deal gooses markets… the hidden signal in gold’s surge… what broke the gold run… the structural case that hasn’t moved… and the tool…
Celebrity SPAC Merger News: 10 Stars Jumping on the SPAC Bandwagon
Investors should follow the latest celebrity SPAC merger news to see where money is moving. Here’s some of the top stars in the game.
Will 2014’s Top Performers Keep Performing?
These three stocks are likely to run higher, given both valuation and business environment.
What To Make Of Tuesday’s Surprising Market Move
Wall Street clearly made up for the shortened trading week with a broad rally on Tuesday. Here’s our new research on 50 stocks in Portfolio…
Maintain Realistic Expectations
The most that can be expected is a small rally and more sideways movement.
Nvidia Still Has 40% Upside – Here’s the Math
Has the “meltdown” begun?… Louis says buy every dip… Nvidia’s surprising upside… the AI infrastructure play Eric spotted first…
The Next AI Boom Could Be Driven by Cybersecurity
Anthropic recently agreed to give the European Union (EU) access to Mythos – its highly advanced cybersecurity-focused AI model – after months of discussions between…
Warsh’s First Move – And the Test That’s Just Getting Started
The FOMC decision is in … what Warsh signaled … why the market’s inflation relief may be premature … the curveball every new Fed chair…
3 Funds to Play the Healthcare Megatrend
Healthcare has been hot in 2013, but more importantly, it’s set up to be a huge mover going forward thanks to several big trends. Here’s…
6 – 10 of 240 results
